Best Peptides for Injury Recovery: Human Evidence

The short answer

We found no peptide that has shown, in a controlled human study, that it speeds recovery from a musculoskeletal injury. The two most-discussed, BPC-157 and TB-500, have animal data; BPC-157 also has a few small uncontrolled human reports, and for TB-500 FDA identified no human data. A 2026 scoping review of six peptides, including these two, concluded that their claimed benefits remain unsubstantiated by current human trials.

If you are hurt, the evidence-based first step is a clinician’s evaluation, not a peptide.

On this page

The honest ranking is short. Two peptides dominate online talk about healing tendons, muscles and joints. Neither has shown in a controlled human trial that it speeds recovery, and for one, FDA identified no clinical studies or human exposure data at all.

The ranking, by strength of evidence

Ordered by the strength of the evidence that it helps with this goal: the type of study first, then its quality and its result. A rank isn’t a recommendation.
Peptide	U.S. status	Strongest evidence
1. BPC-157	Compounded versions: not FDA-approved	Limited human data
2. TB-500	Compounded versions: not FDA-approvedAnimal studies only	Animal studies

How do we decide what is “best”?

“Best” means best evidence, not most popular. For injury recovery we ask:

Is there a randomized, controlled trial in people with an injury, measuring something that matters (function, pain, return to activity)?
If not, what kind of evidence is it? Animal studies, lab-dish studies, case reports and uncontrolled series are weaker and are labeled as such.
What is the regulatory status, and what is known about safety?

By this test, no peptide reaches the top rung for injuries. We rank them by how far each gets.

How do the two peptides compare?

	BPC-157	TB-500
FDA approval	None	None
Randomized trial in humans with an injury	None	None
Limited human data	A retrospective knee series with no control group and a few small pilots; one controlled colitis trial and one phase 1 tolerability study, both reported only as abstracts	None. FDA identified no clinical studies or human exposure data for TB-500 by any route
Animal data	Many models; a scoping review of six peptides, this one included, calls effects in animal models “promising but variable”	Horse and rat studies show it reaches the bloodstream and breaks into fragments; FDA says it remains unknown whether TB-500 has wound-healing properties in living animals, and identified no toxicity studies
Lab-dish data	Not clinical evidence	In one fibroblast study, it appeared not to promote wound closure
Safety knowledge	Insufficient; animal signals potentially related to clotting and the liver	Unknown; FDA identified no clinical or toxicity studies
WADA	Prohibited at all times (S0)	Prohibited (S2)

Sources: FDA’s advisory committee presentations, AJSM 2026, WADA 2026 list. Full details are in our BPC-157 guide.

Why does animal evidence not settle it?

Rodent studies can show that a compound does something in a rodent. They cannot tell you the right route, whether it works in a person, or what harm it does over time. For BPC-157, FDA noted that even among human studies it found none using several of the routes that are now in the news. For TB-500, FDA found no pharmacokinetic data in people at all.

Is TB-500 the same as thymosin beta-4?

No, and the confusion matters. FDA says “thymosin beta-4 and TB-500 are not the same substance.” Thymosin beta-4 is a natural protein of 43 amino acids. TB-500 is a short synthetic fragment of it. FDA says the pharmacology of the unacetylated heptapeptide cannot be directly extrapolated to TB-500, and that it identified no clinical studies or human exposure data for TB-500 by any route; its potential risks in humans are unknown. HHS points instead to the human safety record of the parent protein.

Many websites use the two names interchangeably and cite human trials of thymosin beta-4. Those trials tested different uses and a different substance: eye drops for dry eye (phase 3, 700 participants) and topical treatment of leg ulcers (phase 2, 72 participants), the latter with a primary goal of safety. They are not evidence that injected TB-500 heals tendons or muscle.

What did HHS change on Oct. 30, 2026?

HHS published an interim policy saying it does not intend to take enforcement action against certain pharmacy compounding of BPC-157 acetate and TB-500 acetate, under conditions. It is open to public comment. This is not FDA approval and not a finding that either peptide works. Some points that matter for injury seekers:

TB-500 is covered only as the acetate form, by subcutaneous or intramuscular injection. The policy does not name full-length thymosin beta-4.
BPC-157 and TB-500 together in one product are not covered. The policy requires a single active ingredient (Frier Levitt, secondary source).
The conditions include a patient-specific prescription, batch testing and a registered manufacturer.
FDA’s own review reached a different view of the evidence. FDA’s drug center proposed not adding either peptide to the compounding list, while an advisory committee voted narrowly in favor (8–6–1 for each, per a law-firm account; secondary source).

The accurate description is interim enforcement discretion, under conditions. It is not “FDA approved,” “cleared” or “legal now.”

Is anything being tested right now?

For BPC-157, a randomized pilot after rotator cuff surgery (NCT07803250) with 30 participants was registered but not yet recruiting when we checked. It would be the first controlled human test we know of in an orthopedic setting, and it is small. It has no results. We found no registered trial of TB-500 that we could cite.

What would change our assessment?

A registered, randomized, placebo-controlled trial in people with a defined injury, a pre-specified measure of function or return to activity, and published results. When such a trial appears, this guide will be updated.

What are the risks?

BPC-157: FDA cites insufficient clinical safety information, animal signals potentially related to clotting and the liver, and a potential for immune reactions. Three adverse event reports exist, with uncertain causality.
TB-500: FDA says potential risks in humans are unknown. Its adverse event search returned no reports, and it notes that this reporting is voluntary. That is not evidence of safety.
Quality and identity: for BPC-157, FDA found salts and derivatives sold under the same name and concluded the free base and acetate forms are not well characterized. We do not link to or recommend sellers.
Sport: both are prohibited by WADA.

What should you ask a clinician?

What is my diagnosis, and what does the evidence say about the standard treatments for it?
What recovery milestones should I expect, and what would change the plan?
If I am considering a peptide anyway: what human evidence exists for my specific injury, who would prepare it, and what would we do if I had a reaction?
Does my sport’s anti-doping rule prohibit it?

We do not give doses, cycles or preparation instructions for either peptide.

Frequently asked questions

What peptide is best for tendon repair?

No peptide has been shown in a controlled human study to repair tendons. The best-studied, BPC-157, has animal data and small uncontrolled human reports.

Do BPC-157 and TB-500 work together?

No controlled study supports a combination, and the HHS policy does not cover products with two active ingredients.

Is TB-500 just synthetic thymosin beta-4?

No. FDA says they are different substances.

Are BPC-157 and TB-500 legal?

Neither is FDA-approved. HHS said it does not intend to take enforcement action against certain compounding of both under conditions, on an interim basis. That is not legalization.

How did we rank them?

We rank by the type of evidence first, then its quality and its result. If no peptide has good evidence for a goal, we say so.

Human trialsControlled trials in people, published in a journal, that tested a clinical outcome and showed a benefit. The strongest kind of evidence we report.
Limited human dataSmall, short or inconclusive human studies, including observational studies, uncontrolled trials and controlled trials that did not show a clinical benefit.
Animal studiesResults in animals often don’t carry over to people.
Lab studiesCells or tissue in a dish. An early signal, not an answer.

Sources we checked

FDA presentations to the Pharmacy Compounding Advisory Committee (July 23, 2026)FDA. Accessed October 30, 2026.
FDA CDER proposal on seven peptides (July 2026)FDA. Accessed October 30, 2026.
FDA briefing document on TB-500FDA. Accessed October 30, 2026.
FDA briefing document on BPC-157FDA. Accessed October 30, 2026.
Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed October 30, 2026.
Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed October 30, 2026.
HHS policy, Appendix BOther. Accessed October 30, 2026.
Frier Levitt analysis of the HHS policy (secondary source)Other. Accessed October 30, 2026.
Lee & Padgett 2021, knee injections (PubMed)PubMed. Accessed October 30, 2026.
ClinicalTrials.gov NCT07803250 (rotator cuff pilot, not yet recruiting)ClinicalTrials.gov. Accessed October 30, 2026.
ClinicalTrials.gov NCT03937882 (thymosin beta-4, dry eye, phase 3)ClinicalTrials.gov. Accessed October 30, 2026.
ClinicalTrials.gov NCT00832091 (thymosin beta-4, venous ulcers, phase 2)ClinicalTrials.gov. Accessed October 30, 2026.
WADA 2026 Prohibited ListOther. Accessed October 30, 2026.

Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.